NASDAQ:INMDInMode Stock Price, Forecast & News

InMode's stock was trading at $24.40 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INMD shares have increased by 17.5% and is now trading at $28.66. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InMode.

InMode is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for InMode.

InMode Ltd. (NASDAQ:INMD) released its quarterly earnings data on Wednesday, May, 6th. The healthcare company reported $0.30 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by $0.02. The healthcare company had revenue of $40.44 million for the quarter, compared to the consensus estimate of $38.96 million. InMode had a net margin of 34.56% and a return on equity of 37.88%. The business's revenue was up 32.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.29 EPS. View InMode's earnings history.

4 brokers have issued 1-year price targets for InMode's shares. Their forecasts range from $36.00 to $55.00. On average, they anticipate InMode's stock price to reach $43.25 in the next twelve months. This suggests a possible upside of 50.9% from the stock's current price. View analysts' price targets for InMode.

Headlines about INMD stock have been trending negative on Thursday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. InMode earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news headlines about the healthcare company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about InMode.

InMode saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,810,000 shares, an increase of 20.7% from the June 15th total of 1,500,000 shares. Based on an average daily volume of 887,000 shares, the short-interest ratio is currently 2.0 days. Currently, 11.0% of the company's shares are short sold. View InMode's Current Options Chain.

Some companies that are related to InMode include LivaNova (LIVN), CONMED (CNMD), Zynex (ZYXI), Natus Medical (NTUS), BioLife Solutions (BLFS), AxoGen (AXGN), TransMedics Group (TMDX), Viewray (VRAY), Stereotaxis (STXS), Semler Scientific (SMLR), Cutera (CUTR), BioSig Technologies (BSGM), Fonar (FONR), Soleno Therapeutics (SLNO) and Edap Tms (EDAP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), salesforce.com (CRM), Trade Desk (TTD), AbbVie (ABBV), Alteryx (AYX), Micron Technology (MU), Okta (OKTA) and Square (SQ).

(INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.

InMode trades on the NASDAQ under the ticker symbol "INMD."

InMode's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.08%).

INMD stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc..

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INMD stock can currently be purchased for approximately $28.66.

InMode has a market capitalization of $916.35 million and generates $156.36 million in revenue each year. The healthcare company earns $61.15 million in net income (profit) each year or $1.60 on an earnings per share basis. InMode employs 198 workers across the globe.

The official website for InMode is www.inmodemd.com.

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]